Īdium joins a growing network of partners that Moderna’s been building worldwide.
The most relevant precedent was 10 years ago, when Solvay’s influenza vaccine Influvac formed part of the company’s portfolio. However, it hasn’t marketed a vaccine for a decade now. Raffo has a long experience in licensing agreements with companies of different sizes. This was last July, when the US multi decided to leave Argentina for the second time. In 2021, Raffo took on Eli Lilly’s portfolio, with its focus on diabetes and highly complex segments. See “Moderna: contract signed” in Spanish. Meanwhile, when the pandemic becomes endemic, the Argentine firm may cover private demand through pharmacies. In a second phase, it’s expected that the local drugmaker will manage new agreements between the public sector and Moderna, which is led internationally by global CEO Stephane Bancel. In the first instance, it is expected that Raffo will participate in the management of Moderna’s contract to provide 20 million units of its COVID-19 vaccine in the first quarter of 2022, of which only 21.95% have been delivered to date. Pharmabiz understands that the agreement comprises different stages.
In Argentina, Adium’s presence comes in the form of the local drugmaker Raffo. Adium, a pharmaceutical group based in Montevideo, Uruguay, will commercialise Moderna’s Spikevaxacross Latin America in an agreement that covers 18 countries including Brazil, Mexico, Argentinaand Colombia. Vaccines for COVID-19 continue to dominate the news, and a new player has joined the scene in Latin America. The company, which counts Argentina’s Raffo in its stable, will be the visible face of the US drugmaker’s mRNA-based anti-COVID-19 vaccine. Latin America’s Grupo Adium is to represent Moderna in the region.
0 kommentar(er)
